PLK1 pT210 Antibody, anti-human, REAfinity™
Synonyms: PLK-1, STPK13
RECOMBINANT
Clone:
REA530 | K50-483
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for PLK1 pT210 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-108-198, 130-108-172
Description:
HeLa cells, either left unstimulated (left peak) or stimulated with 5 µM nocodazole for 16 hours, were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-PLK1 pT210 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for PLK1 pT210 Antibody, anti-human, REAfinity™
Overview

Clone REA530 recognizes the human polo-like kinase (PLK1) antigen phosphorylated at threonine 210 (pT210). PLK1 is a key regulator of several important cell-cycle–associated processes, such as centrosome maturation, spindle assembly, sister chromatid cohesion, cytokinesis, and recovery from a DNA-damage–induced arrest. Expression of PLK1 is highly cell cycle regulated; its expression is first induced in G2 and peaks during the early stages of mitosis. PLK1 has been described to be recruited to the centrosomes in G2, as well as to spindle poles and kinetochores during mitosis. Activation of PLK1 is dependent on phosphorylation of a conserved threonine residue (T210) in the T-loop of its kinase domain. Phosphorylation of this residue starts in G2, when PLK1 activity gradually increases until it reaches its full activity when cells enter mitosis. The initial phosphorylation of T210 in G2 is mediated by the kinase Aurora-A, in concert with its cofactor Bora. Since PLK1 is highly expressed in several carcinomas, and expression is inversely correlated with the survival rate of patients in non-small cell lung, head and neck, and esophageal cancer, PLK1 is recognized as a valid prognostic marker.

Additional information: Clone REA530 displays negligible binding to Fc receptors.

Alternative names

PLK-1, STPK13

Detailed product information

Technical specifications

Clone
REA530
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
PLK1 pT210
Molecular mass of antigen [kDa]
68
Distribution of antigen
other
Entrez Gene ID
RRID
AB_2653258, AB_2653257, AB_2653260, AB_2653259

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for PLK1 pT210 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for PLK1 pT210 Antibody, anti-human, REAfinity™
Publications
  1. Hamanaka, R. et al. (1994) Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 5 (3): 249-257
  2. Bruinsma, W. et al. (2014) Bora and Aurora-A continue to activate Plk1 in mitosis. J. Cell. Sci. 127 (4): 801-811
  3. Kakeno, M. et al. (2014) Plk1 phosphorylates CLIP-170 and regulates its binding to microtubules for chromosome alignment. Cell Struct. Funct. 39 (1): 45-59

You have previously chosen International as your location.
What do you want to do?